Most Clicked BIO SmartBrief Stories


1. Amgen's drug for heart failure receives FDA approval

BIO SmartBrief | Apr 16, 2015

Amgen has obtained FDA approval for Corlanor, or ivabradine, as a treatment for chronic heart failure. The approval was supported by a study that demonstrated a lower risk of hospital readmission among patients treated with ivabradine, compared with placebo. Reuters (04/15)


2. Alkermes' assets purchased by Recro

BIO SmartBrief | Apr 15, 2015

Alkermes' assets were acquired by Recro Pharma in a deal worth up to $170 million. Under the terms of the deal, Recro Pharma will gain the global rights to Alkermes' IV/IM meloxicam and the ownership of a CGMP manufacturing facility. Alkermes received an upfront payment of $50 million and is eligible for milestone payments of up to $120 million. Pharmaceutical Business Review Online (04/14)


3. AstraZeneca secures research partnership with PatientsLikeMe

BIO SmartBrief | Apr 15, 2015

A five-year research partnership between PatientsLikeMe and AstraZeneca is designed to harness patient-generated data for pharmaceutical research. The deal gives AstraZeneca access to PatientsLikeMe's database for research that will initially focus on oncology, diabetes, lupus and respiratory disease. BeckersHospitalReview.com (04/13)


4. Sanofi partners with Innate Pharma on antibody-drug conjugates

BIO SmartBrief | Apr 17, 2015

Sanofi and Innate Pharma agreed to collaborate to develop novel antibody drug conjugates using Innate's technology for the conjugation of cytotoxic compounds. Under the terms of the deal, Sanofi will be responsible for assessing payload conjugation to improve the pharmacokinetics of the antibody drug conjugates and will get the option to license the technology with Innate. PharmaTimes (U.K.) (04/16)


5. Mesoblast sells minority stake to Celgene for $44.4M

BIO SmartBrief | Apr 13, 2015

Celgene agreed to pay $44.4 million to acquire about a 4.5% stake in stem cell therapy developer Mesoblast, boosting the former's regenerative and cellular medicine pipeline. The deal entitles Celgene to a six-month right of first refusal on stem cell products from Mesoblast for the treatment of inflammatory bowel disease and oncological diseases. Nasdaq.com (04/12) Bloomberg (04/12)


6. FDA grants breakthrough designation to peanut allergy patch

BIO SmartBrief | Apr 14, 2015

The FDA has offered breakthrough status to DBV Therapeutics' Viaskin Peanut as a treatment for pediatric patients with peanut allergy. The decision was based on midstage clinical trial results submitted by the firm, which found the electrostatic patch to be clinically safe and effective in lessening anaphylaxis risk in peanut allergy sufferers. PharmaTimes (U.K.) (04/09)


7. Eisai enters drug development deal with Genomics

BIO SmartBrief | Apr 14, 2015

Eisai agreed to collaborate with Genomics to aid its drug discovery process using the latter's statistical analyses of genetic association data. Genomics and the integrated human genomics research unit of Eisai will use the genetic data to expedite the development of novel drugs. PharmaTimes (U.K.) (04/13)


8. Boehringer, Hydra enter renal disease drug development pact

BIO SmartBrief | Apr 16, 2015

Boehringer Ingelheim and Hydra Biosciences agreed to collaborate in the discovery of small-molecule inhibitors for use in treating renal diseases. Boehringer will develop and market any inhibitors arising from the partnership. The deal entitles Hydra to an undisclosed upfront fee, milestone payments and research funding. PMLive.com (U.K.) (04/15)


9. Gene therapy developer receives $60M funding boost

BIO SmartBrief | Apr 14, 2015

A Series B funding round pulled in $60 million for Voyager Therapeutics, a gene therapy firm in Cambridge, Mass. The company plans to use the money to finance the advancement of its multiple clinical and preclinical programs. American City Business Journals (04/13)


10. IPO brings in $119M for Aduro Biotech

BIO SmartBrief | Apr 16, 2015

Aduro Biotech secured $119 million in an initial public offering of 7 million shares priced at $17 apiece. Aduro will likely use the money to support CRS-207 and GVAX, a combination of immunotherapies that received breakthrough therapy status for the treatment of pancreatic cancer. FierceBiotech (04/15)




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more